⏳ Fetching live dividend data...
Home › Calculator › HGENQ Dividend Calculator 2026
Humanigen, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in HGENQ → $1.0010004501200205e+38M in 10 years · $8,340,836,334,033,435,000,000,000,000,000,000,000,000,000.00/month
Humanigen, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies that prevent and manage an overactive immune response. At the forefront of its pipeline is lenzilumab, a monoclonal antibody designed to neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF) by binding to it. This drug has been investigated for mitigating the cytokine storm in COVID-19 patients, having successfully completed a Phase 3 trial. It is also currently being evaluated in a Phase 2/3 study supported by the NIH. Furthermore, lenzilumab's potential extends to various other conditions: it is being explored in conjunction with CD19-targeted CAR-T cell therapies and for several inflammatory disorders, including acute Graft versus Host Disease (GvHD) following allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. The company is also investigating its use in chronic myelomonocytic leukemia (CMML) for individuals with RAS pathway mutations. Beyond lenzilumab, Humanigen's pipeline features additional 'Humaneered' monoclonal antibodies. These include ifabotuzumab, which binds to EphA3, and HGEN005, designed to target EMR1. HGEN005 is under development for various eosinophilic conditions, such as eosinophilic leukemia, both as a standalone antibody and as a foundational component for innovative CAR-T constructs. Established in 2000 and based in Short Hills, New Jersey, Humanigen, Inc. recently announced a significant corporate development: on January 3, 2024, the company voluntarily filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the District of Delaware.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open HGENQ position with:
Real after-tax yield depends on where you live and how you hold HGENQ.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 1000000.00% | 999997.20% | $100,000,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 850000.00% | 849997.20% | $85,000,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 800000.00% | 799997.20% | $80,000,000 / yr |
| 🇬🇧 UK ISA | 0% | 1000000.00% | 999997.20% | $100,000,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 912500.00% | 912497.20% | $91,250,000 / yr |
| 🇨🇦 TFSA | 0% | 1000000.00% | 999997.20% | $100,000,000 / yr |
| 🇨🇦 CA Taxable | 25% | 750000.00% | 749997.20% | $75,000,000 / yr |
| 🇦🇺 Super (pension) | 15% | 850000.00% | 849997.20% | $85,000,000 / yr |
| 🇦🇺 AU Taxable | 30% | 700000.00% | 699997.20% | $70,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 736250.00% | 736247.20% | $73,625,000 / yr |
| 🇫🇷 FR Taxable | 30% | 700000.00% | 699997.20% | $70,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
HGENQ pays quarterly — 4 times per year. Next ex-div: TBD.
How HGENQ compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for HGENQ sourced from FMP /financial-growth endpoint — real data, not estimates.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the HGENQ dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Humanigen, Inc. (HGENQ) is currently trading at $0.00, 100% below its 52-week high. The current dividend yield is 1000000.00% based on an annual payout of $2.00 per share.
Humanigen, Inc. (HGENQ) is a healthcare stock currently trading at $0.00 with a dividend yield of 1000000.00%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →